Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.

@article{Abgrall2006ThalidomideVP,
  title={Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.},
  author={Jean-francois Abgrall and Isabelle Guibaud and J N Bastie and Michel Flesch and Jean François Rossi and Laurence Lacotte-Thierry and Françoise Boyer and Philippe Casassus and Borhane Slama and Christian Berthou and Philippe Rodon and Michel Leporrier and Bruno Villemagne and Chantal Himberlin and Kamel Ghomari and Fabrice Larosa and Florence Rollot and Jacqueline Dugay and Christian Allard and Michel Maigre and Françoise Isnard and Robert Zerbib and Jean-Michel Cauvin},
  journal={Haematologica},
  year={2006},
  volume={91 8},
  pages={1027-32}
}
BACKGROUND AND OBJECTIVES In non-randomized studies, thalidomide appeared to be effective in myeloid metaplasia with myelofibrosis (MMM). We compared thalidomide to placebo for treatment of anemia in MMM. DESIGN AND METHODS A prospective phase II B, randomized double-blind multicenter trial comparing thalidomide 400 mg/d with placebo for 180 days was conducted in 52 anemic patients (hemoglobin pounds Sterling 9 g/dL or transfused). The main outcome measure was a 2 g/L increase in hemoglobin… CONTINUE READING
21 Citations
24 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Angiogenesis in acute myeloid leukemia and treatment of AML and myelofibrosis with thalidomide

  • H. Kantarjian
  • ASH 41st annual meeting,
  • 1999
Highly Influential
5 Excerpts

Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis

  • DA Thomas, A Aguayo, FJ. Giles
  • ASH 41 annual meeting,
  • 1999
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…